NAS:MRNA (USA)
Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
200 Technology Square, Cambridge, MA, USA, 02139
Compare
Compare
Traded in other countries / regions
MRNA.Austria
•
M1RN34.Brazil
•
0QF.Germany
•
MRNA.Mexico
•
MRNA.Peru
•
0A45.UK
•
MRNA.USA
Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.9 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 744.86 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 9.45 | |||||
| Beneish M-Score | 0.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 200.9 | |||||
| 3-Year Book Growth Rate | 96.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -30.26 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.44 | |||||
| 9-Day RSI | 67.48 | |||||
| 14-Day RSI | 65.36 | |||||
| 6-1 Month Momentum % | -4.58 | |||||
| 12-1 Month Momentum % | -62.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 1.16 | |||||
| Days Inventory | 123.91 | |||||
| Days Sales Outstanding | 46.52 | |||||
| Days Payable | 15.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.73 | |||||
| Operating Margin % | 70.19 | |||||
| Net Margin % | 63.07 | |||||
| ROE % | 106.42 | |||||
| ROA % | 60.9 | |||||
| ROIC % | 89.85 | |||||
| ROC (Joel Greenblatt) % | 1273.21 | |||||
| ROCE % | 109.81 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.69 | |||||
| Forward PE Ratio | 7.81 | |||||
| PE Ratio without NRI | 5.69 | |||||
| Price-to-Owner-Earnings | 8.46 | |||||
| PS Ratio | 3.59 | |||||
| PB Ratio | 4.07 | |||||
| Price-to-Tangible-Book | 4.07 | |||||
| Price-to-Free-Cash-Flow | 8.72 | |||||
| Price-to-Operating-Cash-Flow | 8.33 | |||||
| EV-to-EBIT | 4.22 | |||||
| EV-to-Forward-EBIT | 5.04 | |||||
| EV-to-EBITDA | 4.14 | |||||
| EV-to-Forward-EBITDA | 4.96 | |||||
| EV-to-Revenue | 2.97 | |||||
| EV-to-Forward-Revenue | 3.03 | |||||
| EV-to-FCF | 7.17 | |||||
| Price-to-Graham-Number | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 13.31 | |||||
| Earnings Yield (Greenblatt) % | 23.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:MRNA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 22,284 | ||
| EPS (TTM) ($) | 32.81 | ||
| Beta | 1.77 | ||
| Volatility % | 54.97 | ||
| 14-Day RSI | 65.36 | ||
| 14-Day ATR ($) | 9.904344 | ||
| 20-Day SMA ($) | 168.651 | ||
| 12-1 Month Momentum % | -62.63 | ||
| 52-Week Range ($) | 115.61 - 497.49 | ||
| Shares Outstanding (Mil) | 391.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moderna Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||